Evidence map›Paper›PMID 26209624›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

Au-ACRAMTU-PEt3 Alters Redox Balance To Inhibit T Cell Proliferation and Function.

P Kent Langston, Mu Yang, Ulrich Bierbach, Derek Parsonage, Leslie B Poole, Madeline J Price, Jason M Grayson

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Human Serum Albumin-Delivered [Au(PEtACS medicinal chemistry letters · 2017
    Article
  3. Autoimmunity in 2015.Clinical reviews in allergy & immunology · 2016
    Review
  4. Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

P Kent LangstonDepartment of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, NC 27101;
Mu YangDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109; and.
Ulrich BierbachDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109; and.
Derek ParsonageDepartment of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC 27101.
Leslie B PooleDepartment of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC 27101.
Madeline J PriceDepartment of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, NC 27101;
Jason M GraysonDepartment of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, NC 27101; jgrayson@wakehealth.edu.
Wake Forest University · US

Funding

Redox control of CD8 T cell proliferation, differentiation and deathR01AI068952 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI GRAYSON, JASON MITCHELL · 2008 to 2012
$1.6M
NIAID NIH HHS R01 AI068952NIAID NIH HHS R01-AI068952
6 · The paper itself

Abstract

Although T cells play a critical role in protection from viruses, bacteria, and tumors, they also cause autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. Unwanted T cell responses during organ transplant, graft-versus-host disease, and allergies are also major clinical problems. Although drugs are available to suppress unwanted immune responses, they have limited efficacy with serious side effects. Thus, new therapeutics limiting T cell activation, proliferation, and function can make an immediate clinical impact. To identify new suppressors of lymphocyte activation, proliferation, and function, we examined the immunosuppressive activity of gold(I) analogs of platinum-acridine antitumor agents. We found that the gold complex Au-ACRAMTU-PEt3 is a potent suppressor of murine and human T cell activation. Preincubation with Au-ACRAMTU-PEt3 suppresses the proliferation of CD4(+) and CD8(+) T cells at a similar concentration as pharmaceutical grade cyclosporine A. Au-ACRAMTU-PEt3 pretreatment decreases the production of IFN-γ, TNF-α, IL-2, and IL-17 by human and murine CD4(+) and CD8(+) T cells. When mice were treated with Au-ACRAMTU-PEt3 during viral infection, the expansion of virus-specific CD8(+) T cells was decreased 10-fold and viral load was elevated. Taken together, these results demonstrate that Au-ACRAMTU-PEt3 has potent immunosuppressive activity that could be used to suppress immune responses during transplantation and autoimmunity.

Indexed as

AcridinesAnimalsCalciumCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCells, CulturedCytokinesDose-Response Relationship, DrugFemaleFlow CytometryHumansLymphocyte ActivationLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMice, Inbred C57BLOrganogold Compounds1-(2-(acridin-9-ylamino)ethyl)-1,3-dimethylthioureaAcridinesCalciumCytokinesOrganogold CompoundsPlatinumUrea

Identifiers

PMID26209624
PMCPMC4854305
OpenAlexW2097742707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.